X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1154) 1154
Book Review (276) 276
Publication (75) 75
Book Chapter (11) 11
Magazine Article (7) 7
Newsletter (3) 3
Conference Proceeding (2) 2
Dissertation (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (881) 881
sevelamer (829) 829
humans (815) 815
urology & nephrology (608) 608
male (420) 420
female (396) 396
hemodialysis-patients (358) 358
middle aged (324) 324
hyperphosphatemia (315) 315
sevelamer hydrochloride (305) 305
polyamines - therapeutic use (287) 287
chelating agents - therapeutic use (262) 262
renal dialysis (255) 255
aged (251) 251
calcium (243) 243
chronic kidney-disease (219) 219
mortality (218) 218
hemodialysis (216) 216
stage renal-disease (207) 207
kidney failure, chronic - complications (198) 198
kidney failure, chronic - therapy (193) 193
hyperphosphatemia - drug therapy (185) 185
phosphate binders (180) 180
phosphates - blood (179) 179
adult (176) 176
calcification (176) 176
calcium - blood (174) 174
phosphorus (173) 173
vascular calcification (171) 171
dialysis patients (169) 169
phosphorus - blood (168) 168
treatment outcome (165) 165
dialysis (159) 159
coronary-artery calcification (158) 158
nephrology (156) 156
phosphate binder (154) 154
lanthanum carbonate (149) 149
chronic kidney disease (148) 148
renal dialysis - adverse effects (141) 141
animals (130) 130
parathyroid hormone - blood (130) 130
phosphates (129) 129
polyamines (126) 126
phosphates - metabolism (124) 124
chronic-renal-failure (122) 122
hyperphosphatemia - etiology (121) 121
parathyroid-hormone (120) 120
serum phosphorus (118) 118
secondary hyperparathyroidism (117) 117
calcium-carbonate (115) 115
phosphate (111) 111
transplantation (109) 109
lanthanum - therapeutic use (108) 108
pharmacology & pharmacy (103) 103
mineral metabolism (98) 98
risk factors (98) 98
kidney failure, chronic - blood (96) 96
calcium carbonate - therapeutic use (95) 95
calcium carbonate (93) 93
chronic kidney failure (93) 93
polyamines - administration & dosage (92) 92
calcinosis - etiology (91) 91
prospective studies (89) 89
renal insufficiency, chronic - complications (87) 87
kidney failure, chronic - drug therapy (86) 86
time factors (86) 86
kidney diseases (85) 85
sevelamer carbonate (80) 80
epoxy compounds - therapeutic use (79) 79
polyethylenes - therapeutic use (79) 79
parathyroid hormone (78) 78
progression (78) 78
calcium - metabolism (77) 77
chelating agents - adverse effects (77) 77
free phosphate binder (73) 73
mortality risk (73) 73
chronic disease (72) 72
disease (72) 72
calcium acetate (71) 71
lanthanum (71) 71
polyamines - pharmacology (68) 68
hyperparathyroidism, secondary - etiology (67) 67
hyperparathyroidism (66) 66
hematology (65) 65
coronary (64) 64
polyamines - adverse effects (64) 64
biomarkers - blood (62) 62
rats (62) 62
aged, 80 and over (61) 61
calcinosis - prevention & control (61) 61
chelating agents - administration & dosage (60) 60
kidney failure, chronic - metabolism (59) 59
medicine & public health (59) 59
disease progression (58) 58
hyperphosphatemia - blood (58) 58
analysis (57) 57
calcium compounds - therapeutic use (57) 57
cardiovascular-disease (57) 57
chelating agents - pharmacology (57) 57
maintenance hemodialysis (57) 57
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1031) 1031
Japanese (56) 56
Spanish (38) 38
French (15) 15
German (12) 12
Polish (6) 6
Portuguese (4) 4
Italian (3) 3
Russian (2) 2
Chinese (1) 1
Czech (1) 1
Dutch (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Kidney Diseases, ISSN 0272-6386, 02/2018, Volume 71, Issue 2, pp. 246 - 253
Journal Article
Kidney International, ISSN 0085-2538, 09/2013, Volume 84, Issue 3, pp. 491 - 500
Journal Article
Revista Española de Patología, ISSN 1699-8855, 2015, Volume 48, Issue 4, pp. 250 - 254
Resumen Sevelamer es un quelante no absorbible del fosfato, usado para tratar la hiperfosfatemia en pacientes con enfermedad renal crónica. La morfología de... 
Pathology | Cristal | Sevelamer chlorhydrate | Kayexalate | Sevelamer carbonate | Sevelamer carbonato | Sevelamer clorhidrato | Kayexalato | Crystal
Journal Article
Nephrology, ISSN 1320-5358, 04/2017, Volume 22, Issue 4, pp. 293 - 300
This short‐term randomized trial of PA21 (sucroferric oxyhydroxide) performed in Japanese haemodialysis patients was able to demonstrate non‐inferiority for... 
PA21 compound | haemodialysis | sevelamer | sucroferric oxyhydroxide | hyperphosphataemia | PHOSPHATE BINDER | TIME | ADHERENCE | TRIAL | DIALYSIS PATIENTS | MAINTENANCE HEMODIALYSIS | UROLOGY & NEPHROLOGY | PILL BURDEN | CHRONIC KIDNEY-DISEASE | Chelating Agents - administration & dosage | Tablets | Humans | Middle Aged | Ferric Compounds - administration & dosage | Male | Parathyroid Hormone - blood | Renal Insufficiency, Chronic - complications | Sevelamer - therapeutic use | Calcium - blood | Hyperphosphatemia - blood | Renal Insufficiency, Chronic - therapy | Time Factors | Female | Renal Insufficiency, Chronic - diagnosis | Sevelamer - adverse effects | Chelating Agents - therapeutic use | Chelating Agents - adverse effects | Sucrose - administration & dosage | Drug Administration Schedule | Sevelamer - administration & dosage | Administration, Oral | Japan | Sucrose - therapeutic use | Sucrose - adverse effects | Treatment Outcome | Biomarkers - blood | Hyperphosphatemia - etiology | Phosphorus - blood | Ferric Compounds - therapeutic use | Renal Dialysis - adverse effects | Hyperphosphatemia - drug therapy | Aged | Ferric Compounds - adverse effects | Hyperphosphatemia - diagnosis | Drug Combinations | Calcium (blood) | Calcium | Hemodialysis | Parathyroid hormone | Phosphorus | Parathyroid | Index Medicus | Original
Journal Article
The American Journal of Surgical Pathology, ISSN 0147-5185, 11/2013, Volume 37, Issue 11, pp. 1686 - 1693
Journal Article
Indian journal of nephrology, ISSN 0971-4065, 05/2019, Volume 29, Issue 3, pp. 191 - 193
Journal Article
American Journal of Kidney Diseases, ISSN 0272-6386, 2015, Volume 66, Issue 3, pp. 479 - 488
Journal Article
Clinical Journal of the American Society of Nephrology, ISSN 1555-9041, 12/2017, Volume 12, Issue 12, pp. 1930 - 1940
Background and objectives: Epidemiologic studies suggest that higher serum phosphaturic hormone fibroblast growth factor 23 levels are associated with increase... 
Creatinine | Phosphates | KLOTHO | Fasting | Renal insufficiency, chronic | Fibroblast growth factor 23 | Cholecalciferol | Cholesterol, LDL | Phosphorus | Chronic kidney disease | Epidemiologic studies | Glomerular filtration rate | Mineral metabolism | Randomized controlled trials | Double-blind method | Random allocation | Fibroblast growth factors | Hypophosphatemia, familial | Sevelamer | Phosphate binders | FGF23 | Fibroblast | LANTHANUM CARBONATE | DIALYSIS PATIENTS | DIETARY PHOSPHATE INTAKE | CALCIUM | CARDIOVASCULAR-DISEASE | HEMODIALYSIS-PATIENTS | UROLOGY & NEPHROLOGY | RENAL-INSUFFICIENCY COHORT | PARATHYROID-HORMONE | SOLUBLE KLOTHO | CHRONIC KIDNEY-DISEASE | Sevelamer - pharmacology | Glomerular Filtration Rate | Double-Blind Method | Humans | Middle Aged | Male | Chelating Agents - pharmacology | Glucuronidase - blood | Renal Insufficiency, Chronic - drug therapy | Renal Insufficiency, Chronic - blood | Phosphorus - urine | Fibroblast Growth Factors - blood | Phosphorus - blood | Cholesterol, LDL - blood | Female | Aged | Sevelamer - adverse effects | Chelating Agents - adverse effects | Index Medicus | Hypophosphatemia, Familial | chronic kidney disease | Renal Insufficiency, Chronic | Epidemiologic Studies | glomerular filtration rate | fibroblast growth factor 23 | sevelamer | Random Allocation | randomized controlled trials | phosphate binders | creatinine | fibroblast | mineral metabolism | Fibroblast Growth Factors | Original
Journal Article
Clinical therapeutics, 09/2019
Aortic stenosis is a common cause of valvular heart disease with no means of prevention. The recognized association between aortic stenosis and serum phosphate... 
Index Medicus
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 08/2018, Volume 2018, Issue 8, pp. CD006023 - CD006023
Background Phosphate binders are used to reduce positive phosphate balance and to lower serum phosphate levels for people with chronic kidney disease (CKD)... 
Bone Diseases | Metabolic [drug therapy | prevention & control]; Calcium [blood | JAPANESE HEMODIALYSIS-PATIENTS | Phosphorus [blood] | Calcium Compounds [adverse effects; therapeutic use] | RANDOMIZED CLINICAL-TRIAL | PERITONEAL-DIALYSIS PATIENTS | Parathyroid Hormone [blood] | Randomized Controlled Trials as Topic | Hypercalcemia [chemically induced] | MEDICINE, GENERAL & INTERNAL | PARATHYROID-HORMONE LEVELS | CORONARY-ARTERY CALCIFICATION | Polyamines [adverse effects; therapeutic use] | Sevelamer Humans | GROWTH-FACTOR 23 | ORAL FERRIC CITRATE | PLACEBO-CONTROLLED TRIAL | Kidney Diseases [blood; complications] | Chronic Disease | Chelating Agents [adverse effects; therapeutic use] | CHRONIC-RENAL-FAILURE | CALCIUM ACETATE/MAGNESIUM CARBONATE | Chronic Kidney Disease-Mineral and Bone Disorder - blood | Polyamines - adverse effects | Humans | Middle Aged | Polyamines - therapeutic use | Parathyroid Hormone - blood | Cause of Death | Sevelamer - therapeutic use | Calcium - blood | Calcium Compounds - adverse effects | Calcium Compounds - therapeutic use | Chronic Kidney Disease-Mineral and Bone Disorder - prevention & control | Adult | Iron Compounds - therapeutic use | Chelating Agents - therapeutic use | Iron Compounds - adverse effects | Lanthanum - adverse effects | Lanthanum - therapeutic use | Chelating Agents - adverse effects | Renal Dialysis - statistics & numerical data | Hypercalcemia - chemically induced | Chronic Kidney Disease-Mineral and Bone Disorder - drug therapy | Disease Progression | Phosphorus - blood | Aged | Index Medicus
Journal Article